| A | B | C | |
|---|---|---|---|
| 1 | main | ||
| 2 | Brand Name | Reverset | |
| 3 | Generic Name | Dexelvucitabine | |
| 4 | Indication | ||
| 5 | Mechanism | ||
| 6 | Administration | ||
| 7 | Economics | ||
| 8 | IP | ||
| 9 | History | Drug Suspended 04/03/2006 | |
| 10 | Clinical Trials | ||
| 11 | Observed increase in frequency of grade 4 hyperlipasemia in patients receiving 200 mg DFC without 3TC or FTC | ||
| 12 | Increased incidence of grade 4 hyperlipasemia was observed in Study 901, the long-term extension of Incyte's first Phase IIb trial (Study 203). |